RESUMO
Objective:To investigate the effects of desloratadine combined with Tongqiao Biyan capsule on allergic rhinitis. Methods:100 patients with allergic rhinitis who received treatment in The Affiliated Hospital of Medical College of Ningbo University from February 2018 to February 2020 were included in this study. They were randomly assigned to receive treatment with either desloratadine tablets (control group, n = 50) or desloratadine tablets combined with Tongqiao Biyan capsule (observation group, n = 50) for 21 days. Improvement in clinical symptoms and changes in inflammatory factors were observed in each group. Results:Scores of nasal itch, nasal obstruction, runny nose, and sneezing in the observation group were (1.42 ± 0.10) points, (1.20 ± 0.13) points, (1.25 ± 0.13) points, and (1.33 ± 0.14) points, respectively, which were significantly lower than those in the control group [(1.80 ± 0.12) points, (1.68 ± 0.15) points, (1.68 ± 0.11) points, (1.68 ± 0.13) points, t = 17.20, 17.10, 17.85, 12.95, all P < 0.001]. After treatment, interleukin -4, -6, -8 levels in the observation group were (16.12 ± 5.05) ng/L, (5.33 ± 2.10) ng/L, (37.16 ± 9.80) ng/L, respectively, which were significantly lower than those in the control group [(21.52 ± 5.58) ng/L, (8.12 ± 2.15) ng/L, (48.55 ± 9.65) ng/L, t = 5.07, 6.56, 5.86, all P < 0.05]. Interferon-γ level was significantly higher in the observation group than in the control group [(26.58 ± 2.58) ng/L vs. (23.68 ± 2.69) ng/L, t = 5.50, P < 0.001]. After treatment, the total score of the quality of life questionnaire was significantly higher in the observation group than in the control group [(61.58 ± 8.57) points vs. (40.98 ± 8.35) points, t = 12.17, P < 0.001]. There was no significant difference in total incidence of adverse reactions between observation and control groups [10.00% (5/50) vs. 14.00% (7/50), χ2 = 0.38, P > 0.05]. Conclusion:Desloratadine combined with Tongqiao Biyan capsule can better improve the symptoms of allergic rhinitis and better reduce inflammation without increasing adverse drug reactions compared with desloratadine alone.